Effect of Low-Dose Aspirin on Chronic Acid Reflux Esophagitis in Rats

Dig Dis Sci. 2018 Jan;63(1):72-80. doi: 10.1007/s10620-017-4840-3. Epub 2017 Nov 15.

Abstract

Background: Clinical role of low-dose aspirin (LDA) in pathogenesis of gastroesophageal reflux disease is by far controversial. This can be attributed to the paucity of basic research detailing the mechanism of LDA-induced esophageal mucosal injury (EI) on underlying chronic acid reflux esophagitis (RE).

Aim: The aim of this study was to clarify the effect of LDA on chronic RE in rats.

Methods: Esophagitis was induced in 8-week-old male Wistar rats by ligating the border between forestomach and glandular portion with a 2-0 silk tie and covering the duodenum with a small piece of 18-Fr Nélaton catheter. Seventy-eight chronic RE rat models were divided into five treatment groups, consisting of orally administered vehicle (controls), and aspirin doses of 2, 5, 50 or 100 mg/kg once daily for 28 days. EI was assessed by gross area of macroscopic mucosal injury, severity grade of esophagitis and microscopic depth of infiltration by inflammatory cells.

Results: Area of esophagitis in animals with aspirin dose of 100 mg/kg/day showed a 36.5% increase compared with controls, although it failed to achieve statistical significance (p = 0.812). Additionally, the rate of severe EI was increased in animals with aspirin dose of 100 mg/kg/day as compared with controls (p < 0.05). The grade of severity correlated with the depth of inflammation (r s = 0.492, p < 0.001).

Conclusions: Maximal dose aspirin (100 mg/kg/day) contributed in exacerbating preexisting EI. LDA (2 and 5 mg/kg/day), on the other hand, did not affect chronic RE in this model. LDA seems to be safe for use in patients with chronic RE.

Keywords: Aspirin; Chronic acid reflux; GERD; Gastroesophageal reflux; Low-dose aspirin; Rat.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Aspirin / administration & dosage*
  • Aspirin / adverse effects*
  • Body Weight
  • Chronic Disease
  • Dose-Response Relationship, Drug
  • Esophagitis, Peptic / pathology*
  • Esophagitis, Peptic / surgery
  • Ligation
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / adverse effects
  • Rats
  • Rats, Wistar
  • Risk Factors

Substances

  • Platelet Aggregation Inhibitors
  • Aspirin